Alan List, MD | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Alan List, MD

Position / Title: 
President and CEO, Moffitt Cancer Center
Award Year: 
Image icon Alan List10.38 KB

President and Chief Executive Officer of Moffitt Cancer Center, Dr. List is internationally recognized for his many contributions in the development of novel, more effective treatment strategies for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). His pioneering work led to the development of lenalidomide (Revlimid®) from the laboratory to clinical trials, which went on to receive fast-track designation from the U.S. Food and Drug Administration and approval for the treatment of patients with MDS and multiple myeloma. This work transformed the natural history of MDS from a premalignant condition that progressed to malignancy requiring aggressive treatment to a condition managed in the outpatient setting with oral agents.

A member of the AAMDSIF Medical Advisory board, he is the author of more than nearly 300 peer-reviewed articles and the Clinician’s Manual on Myelodysplastic Syndromes (2008). He is an active member of the American Society of Clinical Oncology; American Society of Hematology; American Association for Cancer Research; International Society for Experimental Hematology; JP McCarthy Foundation Medical Advisory Committee; and the Southwestern Oncology Group. Dr. List is also a frequent presenter at AAMDSIF conferences, and appears on AA&MDSIF webinars.

Leadership Award Type: